Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01571297
Recruitment Status : Completed
First Posted : April 5, 2012
Last Update Posted : September 23, 2016
Information provided by (Responsible Party):
Motus Therapeutics, Inc.

Brief Summary:
The purpose of this study is to evaluate the effects of RM-131 on gastric emptying, gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in patients with Type 1 and Type 2 diabetes mellitus and gastroparesis. The study is designed to evaluate the efficacy and safety of multiple dose regimens of RM-131. Study drug (RM-131 and placebo) will be administered subcutaneously in a blinded fashion.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Diabetes Mellitus Complications Gastroparesis Drug: RM-131 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 204 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Study Start Date : April 2012
Actual Primary Completion Date : August 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: RM-131 Drug: RM-131
Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.

Placebo Comparator: Placebo Drug: Placebo
Placebo given subcutaneously for 35 days

Primary Outcome Measures :
  1. Effect of RM-131 on gastric emptying time [ Time Frame: Screening and Day 28 ]
    Change from baseline in gastric half-emptying time (t½)

Secondary Outcome Measures :
  1. Effect of RM-131 on symptoms of gastroparesis [ Time Frame: Baseline, daily for 28 days, and Day 35 ]
    Longitudinal change from baseline over time in daily symptom scores from a self administered daily symptom diary

  2. Safety and tolerability of RM-131 [ Time Frame: From Screening through Day 35 ]
    Assessment of adverse events and clinical laboratory evaluations

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures.
  • Type 1 or Type 2 diabetes mellitus with HbA1c ≤11% at screening.
  • Diabetic gastroparesis defined as at least 3 months history of symptoms suggestive of gastroparesis on an ongoing basis.
  • Average Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) > 2.6 during Visit 2.
  • History of nausea and/or vomiting/emesis at least once a week during the 2 weeks prior to Visit 1.
  • Delayed gastric emptying confirmed at screening by abnormal gastric emptying breath test (GEBT), defined as half-emptying time (t½) > 79 minutes.
  • Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to Visit 2.
  • No use of metoclopramide, erythromycin or anti-emetics for at least 2 weeks prior to Visit 2.
  • Body mass index > 18 kg/m2.
  • Female patients must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. Female patients unable to bear children must have this documented in the electronic case report form (eCRF) (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by FSH.

Exclusion Criteria:

  • Currently receiving parenteral feeding; presence of a nasogastric or other enteral tube for feeding or decompression.
  • History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure.
  • History of pyloric injection of botulinum toxin within 6 months of screening.
  • Persistent daily vomiting.
  • Patients with clinical suspicion of upper gastrointestinal obstruction must have been evaluated per standard of care, and obstruction ruled out before screening.
  • Currently taking opiates.
  • Currently taking GLP-1 and amylin analogs.
  • Allergic or intolerant of egg, wheat, milk or algae, as these are components of the GEBT study meal.
  • History of anorexia nervosa, binge-eating or bulimia within 5 years.
  • ALT or AST > 2 X upper limit of normal during screening.
  • History of intestinal malabsorption or pancreatic exocrine disease.
  • Requires hemodialysis or has end-stage renal disease.
  • History of human immunodeficiency virus (HIV) infection.
  • Clinically significant neurologic or psychiatric disorders which are likely to impact compliance with protocol requirements.
  • Poor venous access or inability to tolerate venipuncture.
  • Participation in a clinical study within the 30 days prior to dosing in the present study.
  • Any other reason, which in the opinion of the Investigator, including renal, hepatic or cardiopulmonary disease, or significant acute ECG abnormalities that would confound proper interpretation of the study or expose a patient to unacceptable risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01571297

  Hide Study Locations
United States, Alabama
Dothan, Alabama, United States
United States, Arizona
Tucson, Arizona, United States
United States, Arkansas
North Little Rock, Arkansas, United States
United States, California
Concord, California, United States
Lomita, California, United States
Los Angeles, California, United States
Torrance, California, United States
United States, Florida
Hialeah, Florida, United States
Inverness, Florida, United States
Miami, Florida, United States
West Palm Beach, Florida, United States
United States, Kansas
Wichita, Kansas, United States
United States, Louisiana
Monroe, Louisiana, United States
United States, Maryland
Chevy Chase, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Farmington Hills, Michigan, United States
United States, Mississippi
Jackson, Mississippi, United States
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, North Carolina
Morehead City, North Carolina, United States
Raleigh, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Oregon
Portland, Oregon, United States
United States, Tennessee
Chattanooga, Tennessee, United States
Germantown, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Lubbock, Texas, United States
United States, Virginia
Burke, Virginia, United States
Norfolk, Virginia, United States
Sponsors and Collaborators
Motus Therapeutics, Inc.
Study Director: Chief Development Officer Rhythm Pharmaceuticals, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Motus Therapeutics, Inc. Identifier: NCT01571297     History of Changes
Other Study ID Numbers: RM-131-004
First Posted: April 5, 2012    Key Record Dates
Last Update Posted: September 23, 2016
Last Verified: September 2016

Keywords provided by Motus Therapeutics, Inc.:
Diabetes Mellitus
Delayed Gastric Emptying
Gastrointestinal Motility Disorder

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Complications
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Stomach Diseases
Gastrointestinal Diseases
Digestive System Diseases
Neurologic Manifestations
Signs and Symptoms